Want to join the conversation?
$CMA 2Q15 Q&A: McEvoy of Stephens had a question if $130MM increases in tech and regulatory expenses in FY15 a good run rate for FY16. Karen said that the increases in those expenses were mostly headcount related and so that was something that should stick for the run rate. In tech, expects to have increased expense at least over next few years.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?